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AKT1E17K mutation profiling in breast
cancer: prevalence, concurrent oncogenic
alterations, and blood-based detection
Marion Rudolph1*, Tobias Anzeneder2, Anke Schulz1, Georg Beckmann1, Annette T. Byrne3,6, Michael Jeffers4,
Carol Pena4, Oliver Politz1, Karl Köchert1, Richardus Vonk1 and Joachim Reischl1,5
Abstract
Background: The single hotspot mutation AKT1 [G49A:E17K] has been described in several cancers, with the
highest incidence observed in breast cancer. However, its precise role in disease etiology remains unknown.
Methods: We analyzed more than 600 breast cancer tumor samples and circulating tumor DNA for AKT1E17K and
alterations in other cancer-associated genes using Beads, Emulsions, Amplification, and Magnetics digital
polymerase chain reaction technology and targeted exome sequencing.
Results: Overall AKT1E17K mutation prevalence was 6.3 % and not correlated with age or menopausal stage.
AKT1E17K mutation frequency tended to be lower in patients with grade 3 disease (1.9 %) compared with those
with grade 1 (11.1 %) or grade 2 (6 %) disease. In two cohorts of patients with advanced metastatic disease, 98.0 %
(n = 50) and 97.1 % (n = 35) concordance was obtained between tissue and blood samples for the AKT1E17K
mutation, and mutation capture rates of 66.7 % (2/3) and 85.7 % (6/7) in blood versus tissue samples were
observed. Although AKT1-mutant tumor specimens were often found to harbor concurrent alterations in other
driver genes, a subset of specimens harboring AKT1E17K as the only known driver alteration was also identified.
Initial follow-up survival data suggest that AKT1E17K could be associated with increased mortality. These findings
warrant additional long-term follow-up.
Conclusions: The data suggest that AKT1E17K is the most likely disease driver in certain breast cancer patients.
Blood-based mutation detection is achievable in advanced-stage disease. These findings underpin the need for a
further enhanced-precision medicine paradigm in the treatment of breast cancer.
Keywords: Breast cancer, AKT1E17K mutation, Blood-based mutation detection
Background
Metastatic breast cancer is a major cause of global cancer
mortality and, despite several advances in recent years, is
still largely incurable [1]. Critically, little progress has been
made in the past decade in the evolution of chemothera-
peutic or endocrine therapies to improve overall survival in
patients. Nevertheless, targeted therapies, such as those di-
rected against tumors overexpressing human epidermal
growth factor receptor 2 (HER2), have improved patient
outcomes [2]. Moreover, molecular-characterization stud-
ies in breast cancer have revealed that, in addition to HER2
amplification, tumors may possess numerous other gen-
omic alterations located in oncogenes or tumor suppressor
genes [3, 4]. As specific oncogenic events may be blocked
by targeted therapies, screening for targetable genomic al-
terations may help to identify subpopulations of patients
for whom specific targeted therapy would be beneficial.
One such targetable alteration resides in the v-akt
murine thymoma viral oncogene (AKT). AKT1 is a
member of the serine-threonine kinase class that plays
a key role in cellular processes, including growth, pro-
liferation, survival, and angiogenesis. It is a downstream
mediator of phosphatidylinositol 3-kinase which, along
with AKT1, is a key mediator of proliferation and survival
pathways frequently activated in cancer [5–10]. Tumors
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from patients with breast, colorectal, ovarian, and
leukemic cancers have been shown to harbor activating
somatic mutations in AKT1 [5, 9]. The activation of AKT1
is driven by membrane localization which, in turn, is initi-
ated by the binding of the pleckstrin homology domain to
phosphatidylinositol-3,4,5-trisphosphate or phosphatidyli-
nositol-3,4-bisphosphate, followed by phosphorylation of
the regulatory amino acids serine 473 and threonine 308
[7, 11].
Genetic mutations in the AKT pleckstrin homology do-
main have been reported to disturb the localization behav-
ior and loss of sensitivity towards phosphatidylinositols,
and to have major consequences in AKT functional behav-
ior [5]. For instance, a somatic point mutation at nucleo-
tide 49 introduces a lysine substitution for glutamic acid
at amino acid 17 (AKT1E17K), resulting in a pathologic
association of AKT1 with the plasma membrane and con-
stitutive activation of the enzyme which, in turn, results in
an increased level of AKT phosphorylation and down-
stream molecules independent of upstream, e.g. stimula-
tion of growth factor.
For breast cancer patients, AKT1E17K mutation frequen-
cies between 1.4 % and 8.2 %, with a mean mutation fre-
quency of 3.8 %, have been described [12]. Moreover, the
AKT1E17K mutation appears to be restricted to ductal and
lobular histotypes, and hormone receptor (HR)-positive
breast tumors [13–15]. Interestingly, higher incidences of
AKT1E17K mutations have been reported to occur in benign
papillomas (33 %; 20/61 [defined as papillomas without aty-
pia]), compared with papillary carcinoma (10 %; 1/10) [16].
Several studies have indicated PTEN, PIK3CA, and
AKT1 mutations to be mutually exclusive (i.e. not co-
occurring in the same tumor tissue sample) in individual
tumors [5, 13, 17], suggesting that mutational activation
of the phosphatidylinositol 3-kinase pathway by any one
of these means is biologically equivalent. Alterations in
all three are considered to be potential drivers of human
breast cancer [4, 18]. However, particularly for AKT1E17K
mutation, the precise role in cancer development and
progression in the clinical context is still largely unknown.
To better understand the role of the AKT1E17K mutation
in breast cancer, more than 600 tumor samples from breast
cancer patients were profiled for presence of the AKT1E17K
mutation using Beads, Emulsions, Amplification, and
Magnetics technology (BEAMing; Sysmex Inostics GmbH,
Hamburg, Germany) in tissue and circulating tumor DNA
(ctDNA). Additionally, targeted exome sequencing was
conducted on tumor tissues to reveal any co-existence of
the AKT1E17K mutation with other oncogenic alterations.
Methods
Clinical samples and ethics
Samples were provided by the non-profit organization Pa-
tients’ Tumor Bank of Hope (PATH Biobank, Augsburg,
Germany: http://www.path-biobank.org/index.php/en/
about-path/) [19] as standardized fresh frozen tissue
and blood serum specimens (cohort A; Fig. 1). Pa-
tients provided written, informed consent for the stor-
age of samples and data, follow-up contact, and further
use of samples and data for research purposes. The pro-
cesses described were approved by the Bavarian Data Pro-
tection Commissioner and the ethics committee of the
University of Bonn. Union for International Cancer Con-
trol (UICC) stage I–IV samples were selected based on:
follow-up being possible; no previous treatment; primary
disease; and estrogen receptor (ER)-positive status. The
majority of serum samples (UICC stages I–III) were frozen
within 3 h. Samples from neoadjuvantly treated patients
were also ER-positive, but for relapsed patients both ER-
positive and ER-negative samples were accepted.
A further cohort of paired, concurrently collected breast
cancer tumor samples (formalin-fixed paraffin-embedded)
and blood samples (plasma) from 50 patients with UICC
stage IV disease were obtained by Indivumed GmbH
(Hamburg, Germany) (cohort B; Fig. 1). In 45 of these
cases, the tumor specimen collected was the primary
breast tumor; the remaining five tissue samples were
from biopsies of a metastatic breast cancer lesion. Sam-
ples were collected ethically within the framework of
the “Hamburger Krankenhausgesetz 12a”.
A third cohort (cohort C; Fig. 1) comprised formalin-
fixed paraffin-embedded tumor and plasma samples
from patients with locally advanced or metastatic HER2-
negative breast cancer enrolled in a clinical trial. The
respective study protocol was approved by the institu-
tional review board of each participating institution and
complied with the Declaration of Helsinki, existing Good
Clinical Practice guidelines, and local laws and regula-
tions. All participants provided written, informed con-
sent before enrollment.
Tumor specimens and analysis workflow
Figure 1 depicts the overall sample flow and analysis
plan for the study. In cohort A, 701 breast cancer sam-
ples were obtained from PATH Biobank. Specimens
from untreated, ER-positive breast cancer patients (UICC
stages I–IV) and ER-positive, neoadjuvantly treated pa-
tients as well as of relapsed ER-positive and ER-negative
patient were collected and analyzed by BEAMing. Follow-
up data were collected for the AKT1E17K mutant samples
and a closely matched subset of wild-type samples, based
on clinical parameters e.g. disease stage and age (see in
Additional file 1: Table S1). For the subgroup with UICC
IV disease wild-type samples were selected randomly as
no AKT1E17K mutant sample was found in this patient
group. Matching blood samples (serum) were ordered for
these mutant and wild-type samples. In addition, tissue
samples of all AKT1E17K mutant samples and a subset of
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wild-type samples (see in Additional file 1: Table S2)
were further analyzed by targeted exome sequencing
(FoundationOne®, Cambridge, MA, USA) as described
below.
Additionally, paired tissue and blood samples (plasma)
from cohort B (n = 50) and blood samples (plasma) from
cohort C (n = 35) with known AKT1E17K status (deter-
mined by next-generation sequencing analysis [Asuragen,
Inc., Austin, TX, USA] based on tissue) were analyzed by
BEAMing.
BEAMing
Analysis of tumor tissue and blood samples was per-
formed by Sysmex Inostics. One to three tissue sections
were scraped from glass slides and the entire sample was
used for subsequent isolation of DNA, according to the
manufacturer’s instructions (Epicentre, Madison, WI,
USA). Blood samples were thawed at room temperature
for approximately 15–30 min prior to DNA preparation.
Cell debris was pelleted by centrifugation, and the super-
natant was digested with proteinase K and purified ac-
cording to the QIAamp DNA purification kit (QIAGEN
GmbH, Hilden, Germany). Primers were designed to
amplify a 96 bp region within the abundant consensus
region of the human LINE-1 family. Quantitative real-
time polymerase chain reaction (PCR) was performed in
the presence of SYBR® Green I dye (Molecular Probes®,
Inc., Eugene, OR, USA). An aliquot of the blood DNA
was used as a template for the quantitative real-time
PCR. Dilutions of normal human genomic DNA were
Non-profit organization
(established 2002)
 SOP-guided sample collection at
 seven sites in Germany
 Sample-associated clinical data
 and follow-up program
Sample blinding
Follow-up data obtained for
 matched serum samples
Cohort A
(1) 701 fresh frozen breast
cancer tissue samples
50 matched tissue
(FFPE) and plasma samples 
(3) 38 tissue AKT1E17K-mutant samples
 52 tissue AKT1E17K wild-type samples
BEAMing (Sysmex Inostics;
AKT1E17K, PIK3CA)
 Single-molecule PCRs on
 magnetic beads in water-in-oil 
 emulsions
 Read-out of mutant and wild-type
 beads via flow cytometry
Next-generation sequencing
 FoundationOne® T5a panel
 Over 3000 genetic alterations
 (mutations, deletions, 
 amplifications)
UICC stage IV breast cancer cohort 
(Indivumed)
Cohort B
BEAMing (Sysmex Inostics;
AKT1E17K, PIK3CA [E545K, H1047R,
E542K, H1047L])
35 plasma samples from patients with
known AKT1E17K status based on
next-generation sequencing
data of tissue (FFPE) (Asuragen):
28 cases of wild-type AKT1E17K,
7 cases of mutant  AKT1E17K
Clinical study cohort
(locally advanced or metastatic 
HER2-negative breast cancer)
Cohort C
BEAMing (Sysmex Inostics;
AKT1E17K)
(2) 108 matched serum samples
Fig. 1 Sample flow and analysis. (1) 701 samples of breast cancer tumor tissue were obtained from PATH Biobank and analyzed with BEAMing for
AKT1E17K. (2) For a sub-cohort (108) of BEAMing-identified AKT1E17K-mutant and wild-type samples, follow-up data were collected and matched serum
was ordered. Serum samples were analyzed in a blinded fashion for AKT1E17K (BEAMing). (3) BEAMing-identified AKT1E17K-mutant samples and a sub-
cohort of wild-type samples were analyzed by next-generation sequencing. Abbreviations: AKT1 v-akt murine thymoma viral oncogene, BEAMing Beads,
Emulsions, Amplification, and Magnetics, FFPE formalin-fixed paraffin-embedded, HER2 human epidermal growth factor receptor 2, PATH, Patients’
Tumor Bank of Hope, PCR polymerase chain reaction, SOP standard operating procedure, UICC Union for International Cancer Control
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run in parallel on each plate to serve as reference stan-
dards for the quantification of genomic DNA. Each
sample and reference standard was run in duplicate. The
threshold cycle number was determined using Eppendorf
analysis software (Eppendorf AG, Hamburg, Germany)
with PCR baseline subtracted. In a first pre-amplification
step, multiple loci were amplified in a multiplex PCR reac-
tion. In a second amplification step, nested primers were
used for the amplification of individual amplicons. PCR
products were quality-checked on agarose gel. Pre-
amplified DNA was used for the subsequent BEAMing
assay. Normalization was based on the Invitrogen
Quant-iT™ PicoGreen® dsDNA reagent (Life Technolo-
gies, Carlsbad, CA, USA). The DNA content of PCR
products was quantified by the automated liquid-handling
system from Beckman Coulter, Inc. (Brea, CA, USA) con-
nected to a fluorescence microplate reader. After the
quantification step, samples were diluted in order to ob-
tain a specific amount of pre-amplified DNA. Emulsion
PCR enables the amplification of pre-amplified DNA frag-
ments on the surface of magnetic beads that proceed in
water-in-oil emulsions. Emulsions were subjected to
standard thermal cycling conditions. Subsequently, the
uncovered DNA fragments on the bead surface were hy-
bridized using fluorescently labeled probes specific to the
mutations of interest. The fluorescently labeled beads
were quantified using flow cytometry. For the analysis of
each base change, a separate flow cytometry analysis was
performed. The result of a BEAMing assay is the fraction
of mutant DNA alleles to wild-type DNA alleles present
in a particular sample. This fraction is calculated by divid-
ing the number of mutant beads by the total number of
beads with PCR product (equal to the sum of mutant
beads, mixed beads, and wild-type beads). The sensitivity
for the AKT1 mutation 49 G >A (E17K) is 0.02 % in blood
and 1 % in tissue. The sensitivity is dependent on the pres-
ence of sufficient DNA molecules in the sample.
Targeted sequencing: Foundation Medicine solid-tumor
assay
The Foundation Medicine solid-tumor assay (Founda-
tionOne® T5a panel) is a validated next-generation
sequencing-based cancer genome profiling test that
interrogates 4557 exons of 287 cancer-related genes
with established performance benchmarks supporting
direct clinical use [20]. Briefly, DNA was extracted
from 90 tissue samples received from PATH Biobank
(Fig. 1), 50–200 ng of which underwent whole-genome
shotgun library construction and hybridization-based
capture of 4557 exons from 287 cancer-related genes
and 47 introns from 19 genes frequently rearranged in
solid tumors. Using the HiSeq 2000 platform (Illumina,
Inc., San Diego, CA, USA), hybrid-capture-selected librar-
ies were sequenced to high uniform depth (targeting over
500× coverage by non-PCR duplicate read pairs, with over
99 % of exons at coverage over 100×). Sequence data were
processed using a customized analysis pipeline designed
to accurately detect multiple classes of genomic alter-
ations (base substitutions, indels, focal gene amplifica-
tions, homozygous gene deletions, and selected gene
fusions) in routine clinical specimens. Matched normal
specimens were not analyzed; however, all reported
mutations or classes of mutations have been identified
in previously published cancer-sequencing studies and
were therefore considered likely drivers of cancer. An
alteration was categorized as “known” if reported as
somatic in the COSMIC database (Wellcome Trust Sanger
Institute, Genome Research Limited, Hinxton, Cambridge,
UK). “Likely mutation” indicates a previously unknown,
truncating mutation in a tumor suppressor, and “mutation
of unknown impact” is a variant with unknown somatic/
functional status. All testing was performed in a Clinical
Laboratory Improvement Amendments-certified, College
of American Pathologists-accredited laboratory.
Statistical analyses
BEAMing and targeted sequencing
Likelihood-ratio tests were used to assess potential dif-
ferences in AKT1E17K mutation in breast cancer patients
for the following clinical parameters: histologic subtypes
(invasive ductal, invasive lobular, mixed, others); St. Gallen
criteria [21]; grading; stage of disease (UICC stages I–IV);
distal metastasis (M); lymph-node metastasis (yes/no);
number of lymph-node metastases (categorical: 0, 1, 2, or
3); HER2 status comparing high HER2 expression (3+)
analysis versus low (2+, 1+ or no expression) according to
immunohistochemistry (IHC); menopausal stage (pre or
post); age (ordinal); progesterone-receptor expression; and
tumor size (T; based on the tumor node metastasis classi-
fication). In addition to the respective P-value, Bonferroni-
Holm adjusted P-values were reported to account for mul-
tiple testing. The correlation between mutant allele fre-
quencies, as detected independently by BEAMing and the
Foundation Medicine solid-tumor assay, was assessed by
calculating the Pearson product–moment correlation
coefficient (Pearson’s r). Fisher’s exact test was employed
to compare mutant versus wild-type AKT1 samples for
enrichment of one of the detected mutations in any of the
235 genes. Correction of the P-values for multiple testing
was done by the Benjamini-Hochberg method [22].
Survival estimation
Survival time was calculated based on the time from the
date of surgery until the date of death. For surviving
patients, the date of follow-up was used as a censored
observation. Analyses were performed using a Cox pro-
portional hazards model, with AKT1E17K mutation as the
main factor, together with age at diagnosis and disease
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category (with levels: UICC I-IV, relapse, neoadjuvantly
treated) as covariates. Kaplan-Meier estimates were dis-
played for AKT1 wild-type and mutant status.
Results
AKT1E17K prevalence in breast cancer subgroups
Of the 701 samples in cohort A, 619 samples were eva-
luable for the AKT1E17K mutation: 79 from neoadju-
vantly treated patients, 46 from relapsed patients, and
494 from untreated patients (Table 1). Samples of un-
treated, newly diagnosed patients were categorized ac-
cording to conventional UICC staging: UICC stage I
(T1, N0, M0); UICC stage II (T2, N0–1, M0, and T1,
N1, M0); UICC stage III (any T, N2–3, M0, and T3 or
T4, any N, M0); and UICC stage IV (any T, any N,
M1). Eighty-two (11.7 %) samples had not sufficient
tumor content according to pathologic examination, and
thus could not be evaluated for AKT1 mutations. The fail-
ure rate was distributed as follows between the different
patient sample groups: 11.8 % (19/161) in samples from
patients with UICC stage I disease; 6.6 % (14/212) in sam-
ples from patients with UICC stage II disease; 3.5 % (4/
114) in samples from patients with UICC stage III disease;
and 2.2 % (1/45) in samples from patients with UICC
stage IV disease. As expected, the highest failure rate
(33.6 %; 40/119) was observed in the neoadjuvantly
treated patient group (data not shown).
Overall, the prevalence of AKT1E17K mutation in
tumor samples was 6.3 % (39/619; 95 % confidence
interval 4.5–8.5) (Table 1). The highest mutation fre-
quency (10.9 %; 95 % confidence interval 3.6–23.6) was
observed in samples from relapsed patients, although
this represented a small number of samples (5/46). In
previously untreated patients, an AKT1E17K mutation was
identified in 9.2 % (13/142), 5.6 % (11/198), and 4.5 % (5/
110) of patients with UICC stage I, II, or III disease, re-
spectively (Table 2). No patients with UICC stage IV dis-
ease (0/44) were shown to harbor the AKT1E17K mutation.
Association of AKT1E17K with clinical parameters
No association of AKT1E17K mutation prevalence was
found with respect to age, menopausal stage, histologic
subtype, lymph-node metastasis (N stage), progesterone-
receptor status, or St. Gallen criteria (applying the defin-
ition by Brouckaert et al., whereby tumor grade replaces
Ki-67) [21] considering untreated breast cancer patients
from cohort A (Table 2). However, the latter finding might
reflect that this patient cohort was ER-positive. AKT1E17K
mutations appeared to be associated with lower HER2
expression. 6.3 % (29/457) of patients with an IHC score
of 0, 1+ or 2+ harbored a mutation, compared with 0 %
(0/37) of HER2 3+ patients.
No patients (untreated breast cancer, cohort A) with
UICC stage IV disease harbored the AKT1E17K mutation.
Surprisingly, patients with poorly differentiated tumors
(grade 3) had the lowest prevalence of AKT1E17K mutation
(1.9 %; 2/107), whereas patients with well-differentiated
tumors (grade 1) and moderately differentiated tumors
(grade 2) exhibited a prevalence of AKT1E17K mutation of
11.1 % (8/72) and 6 % (19/315), respectively (Table 2). Of
note, AKT1E17K mutations were observed in patients with
invasive ductal phenotype (6.0 %; 22/368), lobular disease
(4.7 %; 4/89), mixed histotype (10 %; 1/10), or other
(8.7 %; 2/23; papillary and ductal, tubular carcinoma).
Association of AKT1E17K with survival
Survival information was available for 104 patients. The
median follow-up time was 55.3 months, ranging from
1.13 months to the first death, to 99.2 months (sur-
vival). Of these 104 patients, 22 died from any cause
(21.2 %; link of mortality to malignancy unknown), and
82 patients survived until follow-up. Wild-type AKT1
patients had a slightly lower mortality rate (16.4 %; 11/67)
than those presenting with mutant AKT1 (29.7 %; 11/37)
(Fig. 2). The age and disease category adjusted hazard ratio
was 0.232; 95 % confidence interval 0.0710.754 (P = 0.015).
For patients with UICC stage I–III disease, deaths were re-
ported for approximately 2 % (1/42) for the AKT1E17K wild-
type group, compared with approximately 22 % (6/27) for
the mutant group. Recurrence-free survival could not be
determined as these data were only partially available.
Detection of AKT1E17K and PIK3CA mutations in matched
blood samples
As the interrogation of blood-based clinical-mutation de-
tection plays an increasingly important role, we assessed
whether AKT1E17K mutations detected via BEAMing in
tumor tissue could be found in the corresponding ctDNA.
In paired tissue and blood samples from cohort A,
67.0 % concordance for AKT1E17K mutation was found
(Table 3). However, the majority of correctly matched
samples were wild-type AKT1E17K. Detailed analyses of
mismatched samples indicated that samples detected as
Table 1 Prevalence of the AKT1E17K mutation in untreated
(UICC stages I–IV), neoadjuvantly treated, or relapsed breast
cancer patients
Total n AKT1E17K
n (%)
Wild type
n (%)
95 % CI
Neoadjuvanta 79 5 (6.3) 74 (93.7) 2.1–14.2
Relapsedb 46 5 (10.9) 41 (89.1) 3.6–23.6
UICC stages I–IVa 494 29 (5.9) 465 (94.1) 4.0–8.3
Overall 619 39 (6.3) 580 (93.7) 4.5–8.5
DNA was obtained from fresh frozen tumor tissue and analyzed using BEAMing
aER-positive patients
bER-positive and ER-negative patients
Abbreviations: 95 % CI 95 % exact confidence interval, AKT1 v-akt murine
thymoma viral oncogene, ER estrogen receptor, UICC Union for International
Cancer Control
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mutant AKT1E17K in tumor tissue were often not con-
firmed for mutational status in blood samples. Of 35 sam-
ples indicated as mutant AKT1E17K using tumor tissue in
cohort A, the mutational status was confirmed for four
patients using ctDNA, representing an AKT1E17K muta-
tion capture rate of 11.4 % (4/35) for ctDNA. In patients
with UICC stage IV breast cancer, 98.0 % (cohort B) and
97.1 % (cohort C) concordance rates were observed for
the AKT1E17K mutation between paired tumor and blood
samples. In these cohorts, AKT1E17K mutations identified
in tumor tissue could be confirmed in blood in two out of
three patients (cohort B; capture rate of 66.7 % for
ctDNA) and in six out of seven patients (cohort C; capture
rate of 85.7 % for ctDNA). Interestingly, tissue was col-
lected for two of these patients more than 3 years before
the blood sample was collected.
PIK3CA mutations (H1047R, H1047L, E542K, E545K)
were analyzed by BEAMing in the same blood samples
used for AKT1E17K detection (Table 3). For cohort A,
PIK3CA mutation profiling in tissue was obtained by next-
generation sequencing. Comparable with the results for
AKT1E17K, there was 75.3 % concordance between the re-
sults obtained from tissue and blood, and a mutation cap-
ture rate of 22.7 % for ctDNA was found for PIK3CA
mutations in cohort A. Non-matching results were mainly
based on the ability to detect the mutation in tissue but
not blood samples. Only in a single case was a mutation
detected in blood but not in tumor; in another case, a dif-
ferent PIK3CA mutation was detected in tumor compared
with blood. In patients with advanced breast cancer (co-
hort B), 100 % concordance, as well as a 100 % mutation
capture rate for ctDNA versus tissue DNA, was observed
for PIK3CA by BEAMing (Table 3).
Co-existence of the AKT1E17K mutation with oncogenic
driver mutations and further genetic alterations
Comprehensive profiling of AKT1E17K may help to de-
fine a potential role for the mutation in the development
and progression of breast cancer. Thus, we selected the
38 cases identified by BEAMing bearing the AKT1E17K
Table 2 Clinical parameters and association with AKT1E17K
mutation in previously untreated breast cancer patients (cohort A)
Parameter Total
(N = 494)
Mutation P-valuea
(adjusted P-value)
Wild type
(n = 465)
AKT1E17K
(n = 29)
Age, years 0.55 (1.00)
< 35 8 (1.6) 8 (1.7) 0
35–65 255 (51.6) 241 (51.8) 14 (48.3)
> 65 231 (46.8) 216 (46.5) 15 (51.7)
Menopausal statusb 0.34 (1.00)
Pre 77 (15.6) 74 (15.9) 3 (10.3)
Post 381 (77.1) 356 (76.6) 25 (86.2)
UICC stage 0.04 (0.47)
I 142 (28.7) 129 (27.7) 13 (44.8)
II 198 (40.1) 187 (40.2) 11 (37.9)
III 110 (22.3) 105 (22.6) 5 (17.2)
IV 44 (8.9) 44 (9.5) 0
Grade 0.03 (0.38)
1 72 (14.6) 64 (13.8) 8 (27.6)
2 315 (63.8) 296 (63.7) 19 (65.5)
3 107 (21.7) 105 (22.6) 2 (6.9)
Lymph-node
metastasis
(N stage)c
0.17 (1.00)
N0 238 (48.2) 223 (48.0) 15 (51.7)
N1 138 (27.9) 128 (27.5) 10 (34.5)
N2 78 (15.8) 77 (16.6) 1 (3.4)
N3 39 (7.9) 36 (7.7) 3 (10.3)
Distant metastasis
(M stage)
0.02 (0.25)
M0 450 (91.1) 421 (90.5) 29 (100)
M1 44 (8.9) 44 (9.5) 0
Histologyd 0.83 (1.00)
Ductal 368 (74.5) 346 (74.4) 22 (75.9)
Lobular 89 (18.0) 85 (18.3) 4 (13.8)
Mixed 10 (2.0) 9 (1.9) 1 (3.4)
Others 23 (4.7) 21 (4.5) 2 (6.9)
St. Gallen criteriae 0.19 (1.00)
Luminal A 210 (42.5) 194 (41.7) 16 (55.2)
Luminal B1 53 (10.7) 52 (11.2) 1 (3.4)
Luminal B2 231 (46.8) 219 (47.1) 12 (41.4)
HER2 status 0.03 (0.38)
IHC-Score (3+) 37 (7.5) 37 (8.0) 0
IHC-Score
(0 - 2+)
457 (92.5) 428 (92.0) 29 (100)
Table 2 Clinical parameters and association with AKT1E17K
mutation in previously untreated breast cancer patients (cohort A)
(Continued)
PR statusf 0.91 (1.00)
Negative 43 (8.7) 41 (8.8) 2 (6.9)
Positive 375 (75.9) 356 (76.6) 19 (65.5)
aLikelihood-ratio test for the hypothesis that the prevalence of AKT1E17K
mutation in breast cancer patients does not differ based on the respective
clinical parameter. Displayed are only selected parameters
bMissing, n = 36. cMissing, n = 1. dMissing, n = 4. etumor grade was used
instead of Ki-67 for subgrouping. fMissing, n = 76
Abbreviations: AKT1 v-akt murine thymoma viral oncogene, HER2 human
epidermal growth factor receptor 2, IHC immunohistochemistry, PR
progesterone receptor, UICC Union for International Cancer Control
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mutation as well as 52 wild-type samples for targeted
sequencing. Of these, one wild-type sample did not con-
tain sufficient material for targeted sequencing. Mutant
allele frequencies for AKT1E17K, as detected independently
by BEAMing and FoundationOne® targeted sequencing,
correlated well (R2 = 0.8021; Fig. 3a). Mutational status for
just two of the 38 samples (identified by BEAMing as
bearing the AKT1E17K mutation) could not be reconfirmed
by targeted sequencing. However, both cases had a rather
low mutation frequency of 1 % and 2.3 %, respectively. A
total of 235 cancer-related genes were affected by 1131
mutations (amplifications, deletions, mutations). In the
AKT1-mutant cohort (n = 37; one sample with AKT1L52R),
158 genes were affected, with 213 genes affected in the
non-AKT1-mutant cohort. Eighty-one genes were mu-
tated in at least 5 % of samples, among them 13 from
the top 20 list of most frequently mutated breast cancer
genes in the COSMIC database (cancer.sanger.ac.uk)
[23]: (PIK3CA, AKT1, GATA3, TP53, MLL2, MAP2K4,
NF1, ARID1A, CDH1, MED12, PTEN, BRCA1, APC). A
comparison of additional gene alterations associated
with AKT1-mutant versus wild-type tumors identified
some genes that were altered exclusively in AKT1-mu-
tant (SMAD4) or AKT1 wild-type (CDK12, NOTCH3,
AKT3, EMSY, ERBB2, NBN, MYC, FGFR1, IKBKE) tu-
mors (Fig. 3b). In addition, some genes were altered in
both AKT1-mutant and wild-type tumors, but of these
only the PIK3CA mutation was significantly more likely
to be associated with AKT1 wild-type tumors (false
discovery rate <0.1, Fisher’s exact test, after correction
for multiple testing by Benjamini-Hochberg). PIK3CA
mutation frequencies in AKT1 wild-type and mutant
samples were 58 % and 19 %, respectively. Furthermore,
four of the seven PIK3CA mutations in AKT1-mutant
samples had low mutant allele frequencies (<3 %). It is
hypothesized that AKT1 is a driver mutation in breast
cancer which could be supported by identification of
patients bearing no other known cancer-causing muta-
tions. In this context, we identified 12 patients who had
no additional mutations known to drive cancer (Fig. 3c).
While six of these patients had further alterations
which likely contribute to cancer development (e.g.
truncating mutation in tumor suppressor and/or copy
number alterations), no cause other than AKT1 could
be identified for the remaining six cases.
Discussion
The single hotspot mutation in the pleckstrin homology
domain of the AKT1 gene [G49A:E17K] has been de-
scribed in human breast, colon, and ovarian cancers, with
the highest incidence observed in breast cancer [5]. In-
cluding all recently published studies, the reported fre-
quency of this mutation ranges from 1.4 % to 12.5 %, with
a mean frequency of 3.1 % [4, 5, 9, 13, 14, 24–37] (see in
Additional file 1: Table S3). However, the majority of these
studies (14/19) had relatively small sample sizes (under
200) and were associated with broad confidence intervals.
While meta-analysis can support the identification of
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actual mutation frequencies, drawing conclusions about
any association of mutation frequency and clinical param-
eters in this way is challenging, as available clinical infor-
mation varies widely across studies.
We assessed the prevalence of the AKT1E17K mutation
in a large breast cancer cohort (over 600 cases, cohort
A). Our data indicate a prevalence of 6.3 % (39/619;
95 % confidence interval 4.5–8.54) using BEAMing tech-
nology on tumor tissue, which is in agreement with pre-
vious studies (see in Additional file 1: Table S3).
Assessment of ctDNA by BEAMing has been shown to
reliably facilitate analysis of a cancer patient’s mutational
status [38, 39]. However, using matched liquid biopsy
samples, approximately 6 % prevalence could not be
confirmed in this cohort, and the mutation capture rate
in ctDNA was only 11.4 % (4/35). We obtained similar
results for PIK3CA mutation. In samples from patients
with advanced metastatic breast cancer (cohorts B and
C), we obtained 98.0 % and 97.1 % concordance and an
AKT1E17K mutation capture rate of 66.7 % and 85.7 %
for ctDNA, and 100 % concordance and a PIK3CA mu-
tation capture rate of 100 % (cohort B). This is in line
with concordance for AKT1E17K (100 % in three pa-
tients) observed by Perkins et al. in patients eligible for a
phase I study [25]. Interestingly, tissue samples from two
patients in our cohort were collected several years before
blood samples, thereby providing the first hint that the
AKT1E17K mutation is stable during disease development.
Blood samples for cohort A were serum, compared
with plasma used in cohorts B and C. Thus, differences
in mutation detection based on sample type cannot be
excluded. However, considering all data obtained so far,
the low mutation capture rate for ctDNA within cohort
A is likely based on the fact that the majority of patients
had primary-diagnosed early-stage disease without previ-
ous treatment (approximately 55 % for UICC stages I
and II, and 7 % for UICC stage IV). Thus, these data are
in line with previous studies indicating a stage-
dependent limitation for mutation detection by ctDNA
profiling [40–43].
The AKT1E17K prevalence determined in our study was
not correlated with age or menopausal stage. In line with
findings described by Stemke-Hale et al. [14], we did not
find any tumors expressing HER2 at a level of IHC-Score 3+
also bearing the AKT1E17K mutation (0/37). Interestingly, we
identified one HR-negative patient as having mutated
AKT1E17K (1/10; 3/20 for HR-positive) within the group of
relapsed cases. Thus, it is possible that AKT1E17K mutation
Table 3 Comparative mutation analysis using blood and tissue samples of the same patients
AKT1E17K PIK3CA
Cohort A Cohort B Cohort C Cohort A Cohort B
Total paired samples analyzed, n 94 50 35 71 50
Mismatched samples, pairs, n
Tumor Blood - -
AKT1 WT AKT1E17K 0 0 0 - -
AKT1E17K AKT1 WT 31 1 1 - -
PIK3CA WT PIK3CA mut - - - 1 0
PIK3CA mut PIK3CA WT - - - 16 0
PIK3CA mut PIK3CA mut - - - 1 0
Total mismatched, pairs, n 31 1 1 18 0
Matched samples, pairs, n
AKT1 WT AKT1 WT 59 47 28 - -
AKT1E17K AKT1E17K 4 2 6 - -
PIK3CA WT PIK3CA WT - - - 50 37
PIK3CA mut PIK3CA mut - - - 5 13
Total matched, pairs, n 63 49 34 55 50
Concordance (%) 67.0 98.0 97.1 75.3a 100
Mutation capture rate in ctDNA (%) 11.4 66.7 85.7 22.7 100
Cohort A: Analysis of AKT1E17K mutations using BEAMing for fresh frozen tumor tissue samples and blood samples (serum), and analysis of PIK3CA mutations
(H1047R, H1047L, E542K, E545K) using BEAMing for blood samples (serum) and next-generation sequencing for fresh frozen tumor tissue samples. Cohort B: Both
AKT1E17K and PIK3CA mutations (H1047R, H1047L, E542K, E545K) were determined in tissue (FFPE) and blood (plasma) using BEAMing. Cohort C: Analysis of
AKT1E17K using BEAMing for blood samples (plasma) and next-generation sequencing for tissue samples (FFPE). “Matched samples” indicates that the same result
was obtained using tissue or blood samples. “Mismatched samples” indicates that different results were obtained using tissue and blood samples. aCalculation
was based on total measured events (n = 73), as in one sample, two PIK3CA mutations were detected of which only one matched
Abbreviations: AKT1 v-akt murine thymoma viral oncogene, BEAMing Beads, Emulsions, Amplification, and Magnetics, FFPE formalin-fixed paraffin-embedded,
mut mutant, WT wild type
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may not be restricted to HR-positive breast cancer [14].
However, any predominance in HR-positive breast cancer as
described for PIK3CA cannot be excluded because of the
low number of cases in our HR-negative cohort [26].
It has been described that AKT1E17K mutation could not
be found in medullary and mucinous histotypes and is re-
stricted to ductal and lobular histotypes [13, 15]. In con-
trast to this, we found the mutation also in a relapsed
patient with mucinous carcinoma (grade 1, ER/progester-
one receptor unknown). Thus, our data support the asser-
tion that large cohorts containing sufficient numbers in
each clinical subgroup are required to reliably evaluate
mutation association with histotype or other clinical pa-
rameters. Furthermore, in this cohort, prevalence of the
AKT1E17K mutation was lower in patients with grade 3
disease compared with those with grade 1 or grade 2
disease. Comparable data were obtained for PIK3CA mu-
tations in breast cancer patients [26].
This leads to the question as to why AKT1E17K preva-
lence is reduced in the more advanced disease setting. It
has been hypothesized that AKT activation confers a
selective advantage during early HR-positive tumorigen-
esis but inhibits tumor dissemination during progression
[14]. This is supported by the observation that over-
activation of AKT drives initiation of tumorigenesis but
inhibits invasion and metastasis in an ERBB-2-induced
mammary tumor model [44]. Accordingly, AKT1E17K-mu-
tant clones could play a role during early tumorigenesis
and – contradictory to the assumption of clonal stability –
be overgrown during disease progression from grade 1 to
3 by other clones.
On the other hand, assuming that tumors bearing the
AKT1E17K mutation are rather more aggressive and rapidly
growing, one could hypothesize that patients bearing this
tumor phenotype could present earlier and hence be diag-
nosed at an early disease stage (e.g. UICC stage I/grade 1),
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as inferred in the present work. Consequently, patients
bearing the AKT1E17K mutation would already be under-
going therapy when their disease reached UICC stage IV/
grade 3 and would therefore not be identifiable in a first-
diagnosis cohort as used herein. However, they would be
identifiable in a cohort not limited to first-diagnosis pa-
tients corresponding to our cohort B (3 AKT1E17K-mu-
tated patients out of 50 according to tissue analysis) or
relapsed patients (5/45). Compared with patients with
wild-type AKT1, patients with AKT1E17K mutations would
also therefore be expected to relapse sooner and/or sus-
tain disease-related death. Long-term follow-up data from
patients are required in order to confirm this hypothesis.
Although low sample numbers precluded comprehen-
sive analysis, initial follow-up survival data indicate in-
creased death rates in early-stage disease (UICC stages
I–III) for patients with mutant AKT1E17K versus wild
type. Thus, AKT1E17K could be a negative prognostic fac-
tor. However, in contrast to this, it has been reported that
disease did not recur in six AKT1E17K-mutant patients
[14]. Further collection of follow-up data in collaboration
with PATH Biobank is planned. This will facilitate con-
firmation of the impact of AKT1E17K (and also other mu-
tations measured with the FoundationOne® panel) on
disease progression or survival.
It has been described that PIK3CA and AKT1 mutations
are not co-occurring in individual tumors [5]. However,
the sample size was insufficient to document statistical
significance, and an exception (based on one case only)
has been noted in another study where the patient bore
both PIK3CA and AKT1 mutations [13]. Our data clearly
indicate that both mutations can co-exist within one
tumor. However, PIK3CA mutations are rather under-
represented in AKT1E17K-mutant compared with wild-
type samples. Moreover, in AKT1-mutant samples, the
PIK3CA allele frequencies were lower than the AKT1E17K
allele frequency. Thus, it is possible that the AKT1E17K
mutation occurred earlier in development in these specific
cancer samples. Of course, since our analysis was per-
formed on the entire tumor tissue, the possibility that
AKT1 and PIK3CA mutations existed in different cells
within the tumor could not be excluded.
AKT1E17K may represent a bona fide oncogene in the
context of human luminal breast cancer. Recently, knock-
in of the mutation into a luminal breast cancer cell-line
model against a PIK3CA wild-type background was shown
to restore pathway signaling, proliferation, and tumor
growth in vivo [18]. Our data support the oncogenic role
of AKT1E17K, as 16.2 % (6/37) of all AKT1-mutant patients
were identified as having no other mutation or genetic
alterations known to drive their disease or which were
likely involved in disease generation or progression. Thus,
AKT1E17K in these patients was the most likely disease
driver. To date, there are several clinical programs in place
addressing AKT as a potential therapeutic target [45–47].
ATP-competitive inhibitors and allosteric inhibitors have
shown promising efficacy in AKT1-mutant cancers in pre-
clinical studies [48].
Conclusions
Our data suggest that conclusions regarding the prevalence
of rare mutations such as AKT1E17K may only be drawn
using large cohorts with associated well-documented clin-
ical data. Integrative combined analyses of data emerging
from such studies coupled with appropriate follow-up pro-
grams may support the interrogation of mutation pheno-
type, incidence, and association with disease initiation or
progression into treatment decisions. Thus, outcomes from
these analyses may ultimately be employed in the design of
appropriate clinical trials towards an enhanced-precision
medicine paradigm in breast cancer.
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